Overview
- The Body Scan 2 measures more than 60 biomarkers in about 90 seconds using eight foot electrodes and a retractable handle with four electrodes to create a full‑body circuit.
- New modalities include a six‑lead ECG, Impedance Cardiography for heart pumping performance, and ultra‑high‑frequency Bioimpedance Spectroscopy for cellular and metabolic assessment.
- Withings claims an AI model can flag arterial hypertension risk without a cuff and the ECG can detect atrial fibrillation, with both features requiring FDA clearance in the U.S.
- Noninvasive metabolic tracking uses bioimpedance and stimulated foot‑sweat signals to surface signs of glycemic dysregulation and cellular health, presented as early‑warning insights rather than diagnostics.
- The device adds a Health Trajectory score, moves the display into the handle, supports Wi‑Fi/Bluetooth syncing, is rated for up to 15 months per charge, and targets Q2 2026 availability at about $599 pending approvals.